If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Diagnosis and follow-up of hematologic malignancies often involve both cytogenetic
and molecular testing, and while they target different types of genetic aberrations,
the two have findings that are complementary. Chromosome analysis provides a low-resolution
genome-wide view, whereas, next-generation sequencing (NGS) offers a high resolution
view but may overlook the larger picture. One way in which these technologies complement
each other is in the identification of copy number aberrations (CNAs). CNAs can be
determined from NGS data by quantitatively assessing the number of amplicon reads
(coverage) from one case compared to all cases in the batch (log normalized copy number
state or LN-CNS), which can then be correlated with concurrent karyotype studies.
We reviewed hematologic malignancy cases received in our laboratories over a period
of one year to identify samples with possible loss of heterozygosity (LOH) for the
TP53 locus based on NGS allele frequency. Of 21 cases with possible LOH, loss of 17p was
confirmed in 14 cases by cytogenetic studies, either karyotype or fluorescence in
situ hybridization (FISH). Of the seven cases without evidence of a loss by cytogenetics,
six revealed a normal LN-CNS by NGS, suggestive of copy-neutral LOH. The remaining
case showed abnormal LN-CNS by NGS. Importantly, this case had an apparently balanced
translocation involving 17p (confirmed by FISH) that was discrepant with the NGS results.
Overall, we conclude that using the read depth from NGS panels may aid in determining
the genetic mechanism of disease. To illustrate the usefulness of CNA detection via
NGS, we present three interesting hematologic malignancy cases with LOH for the TP53 locus in patients with complex karyotypes but no TP53 loss identified by cytogenetic testing, highlighting how integrating molecular and
cytogenetic methods can provide a more complete genetic diagnosis.
To read this article in full you will need to make a payment